Bayforest Capital’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Bayforest Capital's KYMR Position: Q3 2026 in Review
Bayforest Capital reduced its Kymera Therapeutics (KYMR) stake by 63% in Q3 2026, selling an estimated $67.8K and leaving 352 shares worth $39.4K. The position accounts for 0.06% of the portfolio, ranked #566.
Bayforest Capital first reported a position in KYMR in Q1 2026 and has held it in 3 quarters since. The position peaked at $129K in Q1 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Bayforest Capital held 352 shares of Kymera Therapeutics worth $39.4K as of Q3 2026.
- Bayforest Capital sold 592 Kymera Therapeutics shares in Q3 2026, an estimated $67.8K.
- Kymera Therapeutics made up 0.06% of Bayforest Capital's portfolio in Q3 2026, its #566 holding.
- Bayforest Capital first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Bayforest Capital's Kymera Therapeutics position peaked at $129K in Q1 2026.
- 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Bayforest Capital's 13F filing for Q3 2026, filed 3 Nov 2026.